Status:

UNKNOWN

Probiotics in Patients With Primary Sclerosing Cholangitis

Lead Sponsor:

UMC Utrecht

Conditions:

Primary Sclerosing Cholangitis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ...

Detailed Description

I. INTRODUCTION Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease characterized by multifocal strictures of intrahepatic and extrahepatic bile ducts, which frequently lea...

Eligibility Criteria

Inclusion

  • Diagnosis of PSC based on characteristic findings on cholangiography, or based on the triad: typical histological findings in a liver biopsy, elevated serum alkaline phosphatase and presence of inflammatory bowel disease
  • Presence of inflammatory bowel disease
  • elevated serum alkaline phosphatase
  • age ≥ 18 years
  • informed consent

Exclusion

  • Pregnancy
  • use of probiotics within one month before the study
  • use of antibiotics within one month before the study
  • a history of bacterial cholangitis

Key Trial Info

Start Date :

January 1 2005

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00161148

Start Date

January 1 2005

End Date

May 1 2006

Last Update

January 9 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UMC Utrecht

Utrecht, Utrecht, Netherlands, 3508 GA